Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group.

OBJECTIVE To assess the value of measuring circulating concentrations of mediators (endotoxin, tumor necrosis factor-alpha [TNF-alpha], interleukin-1 beta [IL-1 beta], and interleukin-6[IL-6]) and their endogenous antagonists (antiendotoxin core antibody [EndoCAb], interleukin-1 receptor antagonist [IL-1ra], and soluble TNF receptors [sTNF-R]) in predicting mortality and organ failure in sepsis syndrome. DESIGN Cohort study with a follow-up period of 30 days. SETTING Intensive therapy units of five tertiary referral centers in Scotland. SUBJECTS A total of 146 intensive therapy unit patients with sepsis syndrome underwent repeated sampling during a 10-day period following admission to an intensive therapy unit. MAIN OUTCOME MEASURES Circulating concentrations of mediators and antagonists were compared in survivors and nonsurvivors. RESULTS Median Acute Physiology and Chronic Health Evaluation II score was 23 (range, 8 to 40). Mortality at 30 days was 49%. On entry to the study, circulating endotoxin was detected in 66% of patients, TNF-alpha in 14%, and IL-1 beta in 29%. Levels did not predict mortality or organ failure. Patients with IL-6 concentrations in excess of 3000 pg/mL had an increased mortality rate (64% vs 40%, P = .02). The incidence of IgG EndoCAb depletion on entry to the study was 26% in nonsurvivors and 10% in survivors (P = .02). Initial concentrations of both type I and type II sTNF-R were significantly higher in nonsurvivors (P < .01). Initial circulating IL-1ra concentrations were not of value in predicting mortality. Cytokine antagonists were present in concentrations 30- to 100,000-fold greater than their corresponding cytokine. CONCLUSION The observed high circulating levels of the cytokine antagonists IL-1ra and sTNF-R and the relatively small proportion of patients developing EndoCAb depletion may contribute to the limitations of therapies that aim to augment natural defenses against endotoxin or the proinflammatory cytokines.

[1]  J. Balibrea,et al.  NO2/NO3 and cytokine plasma profiles under different postoperative parenteral nutrition regimens. , 1996, Nutrition.

[2]  R. F. Johnston,et al.  Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .

[3]  R. Bone,et al.  Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.

[4]  C A Smith,et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.

[5]  M. Lamy,et al.  Sequential Anti‐core Glycolipid Immunoglobulin Antibody Activities in Patients With and Without Septic Shock and Their Relation to Outcome , 1993, Annals of surgery.

[6]  J. Vincent,et al.  Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. , 1993, Chest.

[7]  T. Kishimoto,et al.  gp130, common signal transducer for cytokines including IL-6 , 1993 .

[8]  C. Sprung,et al.  Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. , 1992, The Journal of infectious diseases.

[9]  J. Hurley,et al.  Antibiotic-induced release of endotoxin: a reappraisal. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  M. Brockhaus,et al.  Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. , 1992, The Journal of clinical investigation.

[11]  B. Hazenberg,et al.  Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute‐phase proteins during the treatment of severe sepsis in humans , 1992, Critical care medicine.

[12]  C. Dinarello,et al.  Production of interleukin-1-receptor antagonist during experimental endotoxaemia , 1991, The Lancet.

[13]  M. Glauser,et al.  Septic shock: pathogenesis , 1991, The Lancet.

[14]  I. Schedel,et al.  Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. , 1993 .

[15]  Jerome J. Schentag,et al.  A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis , 1991 .

[16]  T. Calandra,et al.  High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. , 1991, The American journal of medicine.

[17]  C. Sprung,et al.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .

[18]  S. Wright,et al.  Multiple receptors for endotoxin. , 1991, Current opinion in immunology.

[19]  R. Danner,et al.  Endotoxemia in human septic shock. , 1991, Chest.

[20]  J. Schellekens,et al.  Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-l, Interferon-α, and Interferon-γ in the Serum of Patients with Septic Shock , 1990 .

[21]  L. G. Thijs,et al.  Increased plasma levels of interleukin-6 in sepsis [see comments] , 1989 .

[22]  M. Lamy,et al.  Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. , 1989, Critical care medicine.

[23]  D. G. Smith,et al.  Changes in anti-endotoxin-IgG antibody and endotoxaemia in three cases of gram-negative septic shock. , 1989, Circulatory shock.

[24]  M. A. Martin,et al.  Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs placebo. , 1989, JAMA.

[25]  T. Clemmer,et al.  Sepsis syndrome: a valid clinical entity , 1989 .

[26]  C. Nathan,et al.  Macrophages rapidly internalize their tumor necrosis factor receptors in response to bacterial lipopolysaccharide. , 1989, The Journal of biological chemistry.

[27]  T. Clemmer,et al.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.

[28]  D Greenwood,et al.  An analysis of community and hospital-acquired bacteraemia in a large teaching hospital in the United Kingdom. , 1987, The Quarterly journal of medicine.

[29]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[30]  Cerra Fb,et al.  Hypermetabolism, organ failure, and metabolic support. , 1987 .

[31]  R. Goris,et al.  Multiple-organ failure. Generalized autodestructive inflammation? , 1985, Archives of surgery.

[32]  W. Knaus,et al.  APACHE II: a severity of disease classification system. , 1985 .

[33]  L. S. Young,et al.  Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core. , 1983, The Journal of clinical investigation.

[34]  J. Whicher,et al.  AN Evaluation of the Hyland Laser Nephelometer PDQ System for the Measurement of Immunoglobulins , 1978, Annals of clinical biochemistry.

[35]  R. Gilbert.  Mechanisms of the hemodynamic effects of endotoxin. , 1960, Physiological reviews.